Aminophylline solution for injection 2.4% 5ml ampoules 10 pcs Grotex Ltd.


Aminophylline solution for injection 2.4% 5ml ampoules 10 pcs Grotex Ltd.



Active substance:
1 ml contains: aminophylline (aminophylline) (on dry substance) – 24 mg.
Water for injections.
Product form:
A solution for intravenous administration of 24 mg / ml. 5 or 10 ml ampoules.
Hypersensitivity to the drug, as well as other xanthine derivatives: caffeine, pentoxifylline, theobromine. Severe hypotension or hypertension, paroxysmal tachycardia, arrythmia, myocardial infarction with cardiac arrhythmia, epilepsy, increased convulsive readiness, hypertrophic obstructive cardiomyopathy, thyrotoxicosis, pulmonary edema, severe coronary insufficiency, hepatic and / or renal failure, hemorrhagic stroke, bleeding into the retina eye, bleeding in the recent history, the period of lactation.
With caution: pregnancy, neonatal period, age over 55 years, and uncontrolled hypothyroidism (possibility of cumulation), widespread atherosclerosis, sepsis, prolonged pyrexia, gastroesophageal reflux, peptic ulcer and duodenal ulcer (in history), prostate adenoma. The drug is not recommended for intravenous administration to children under 14 years (due to possible side effects).
2.4% 5 ml
Bronchial obstruction in asthma, bronchitis, emphysema, asthma, heart (mainly cupping); hypertension in the pulmonary circulation. Cerebral blood flow of ischemic (in combination therapy to reduce intracranial pressure). Left ventricular failure with bronchospasm and respiratory failure by type of Cheyne-Stokes (in the complex therapy).
Interaction with other drugs
Ephedrine, beta adrenostimulyatorov, caffeine and furosemide increase the effect of the drug. Increases the likelihood of side effects of glucocorticoids, mineralokortikosteroidov (hypernatremia), funds for general anesthesia (increased risk of ventricular arrhythmias). In combination with phenobarbital, phenytoin, rifampin, isoniazid, carbamazepine or sulfinpyrazone aminophylline observed decrease in efficiency, which may require an increase in applied doses. Aminoglutethimide, moratsizin, as inducers of microsomal oxidation increase aminophylline clearance, which may require increasing the dose. Clearance of the drug is reduced by assigning it in combination with an antibiotic macrolide, lincomycin, allopurinol, cimetidine, isoprenaline, beta-blockers, that may require dose reduction. Oral estrogen-containing contraceptives, antidiarrheal drugs, intestinal sorbents weaken and H2-histamine blockers, calcium channel blockers slow, mexiletine enhance the effect (associated with the cytochrome P450 enzyme system and alter the metabolism of aminophylline). In the case of use in combination with enoxacin and other fluoroquinolin, small doses of ethanol, disulfiram, recombinant interferon alpha, methotrexate, propafenone, thiabendazole, ticlopidine, verapamil and vaccination against influenza intensity aminophylline steps may increase, which may involve reducing its dosage. The drug inhibits the therapeutic effect of lithium carbonate and beta-blockers. Appointment of beta-blockers prevent the bronchodilatory effect of aminophylline and may cause bronchospasm. Aminophylline potentiates the effect of diuretics due to increase glomerular filtration and tubular reabsorption reduction.
Be wary appoint eufillin simultaneously with anticoagulants, with theophylline or other derivatives of purine. Not recommended for use with aminophylline a means of stimulating the central nervous system (increases neurotoxicity). The drug should not be used with solutions of dextrose, is not compatible with the solution of glucose, fructose and levulose. It should take into account the pH of the mixed solutions: a pharmaceutically compatible acid solutions.
In case of overdose observed facial flushing, insomnia, motor agitation, anxiety, photophobia, anorexia, diarrhea, nausea, vomiting, epigastric pain, gastrointestinal bleeding, tachycardia, ventricular arrhythmias, tremors, generalized convulsions, hyperventilation, a sharp drop in blood pressure . In severe poisoning may develop epileptic seizures (especially in children without incurring any precursors), hypoxia, metabolic acidosis, hyperglycemia, hypokalemia, necrosis of skeletal muscles, confusion, renal failure with myoglobinuria.
Treatment of overdoses depends on the clinical picture includes abolition of the drug, stimulating its excretion from the body (diuresis, hemosorbtion, plasmasorption, hemodialysis, peritoneal dialysis) and assigning symptomatic drugs. For relief of convulsions diazepam used (injection). It can not be used barbiturates. In severe intoxication (aminophylline content of more than 50 g / l) recommended hemodialysis.
pharmachologic effect
Pharmacological group:
Bronchodilatory agent.
The drug inhibits phosphodiesterase increases the accumulation of cAMP in tissues, inhibit adenosine (purine) receptors; It has the ability to inhibit the transport of calcium ions across cell membranes channels reduces smooth muscle contractile activity. It relaxes the muscles of the bronchi, suppresses bronchoconstriction. It has moderate inotropic and diuretic action. Aminophylline reduces vascular resistance, decreases the tonus of blood vessels (mainly the brain, skin and kidney), dilates coronary vessels, lowers blood pressure in the pulmonary artery, improves contraction of the diaphragm, increases mucociliary clearance, inhibits the release of mediators (histamine and leukotrienes) from mast cells, stimulates the respiratory center, enhances the release of adrenaline by the adrenal glands, inhibits platelet aggregation, improve microcirculation.
60% of the aminophylline (healthy adults) and 36% (in newborns) binds to plasma proteins and is distributed in the blood, extracellular fluid, and muscle tissue. Eufillin crosses the placental and blood-brain barriers, does not accumulate in fatty tissue. 90% of the drug is metabolized in the liver. Metabolites are excreted by the kidneys, 7-13% of the drug is released in unaltered form. The half-life is in non-smoking adults from 5 to 10 hours, in children older than 10 months, from 2.5 to 5 hours. Smoking and alcohol significantly affect the metabolism and excretion of the drug, in particular in smokers, this period is greatly reduced and ranges from 4 to 5 hours. Excretion of the drug is prolonged in patients with respiratory insufficiency, liver and heart failure, viral infections and hyperthermia.
Pregnancy and breast-feeding
The appointment of the drug during pregnancy should be weighed against the expected benefit to the mother and the potential risk to the fetus. If necessary, use during lactation breast-feeding should be discontinued.
Conditions of supply of pharmacies
On prescription.
side effects
On the part of the gastrointestinal tract: gastroesophageal reflux (heartburn), exacerbation of peptic ulcer disease.
Central nervous system: headache, restlessness, anxiety, irritability, dizziness, insomnia, tremor; rare – cramps, nausea, vomiting.
From the cardiovascular system: palpitations, tachycardia, false angina, cardiac arrhythmias, increased frequency of attacks of angina, high blood pressure reduction until collapsing – under rapid intravenous administration.
Allergic reactions: skin rash, itchy skin, exfoliative dermatitis, feverish reaction.
Local reaction at the injection site – redness, tenderness, induration.
Other: chest pain, tachypnea, albuminuria, hematuria, hypoglycemia, sweating, sensation of flushing, increased diuresis.
special instructions
The drug is prescribed with caution in patients with severe liver and kidney, gastric ulcer and duodenal ulcer. Elderly patients are recommended to reduce the dose of the drug due to its slow clearance from the body. Smoking patients are recommended to increase the dose in an accelerated excretion of the drug from the body.
Storage conditions
In the dark place at a temperature of from 10 to 25 C. Freezing unacceptable. Keep out of the reach of children.
Dosing and Administration
The vein adult is administered slowly (over 4-6 minutes) of 5-10 ml of the drug (0.12 – 0.24 g) which had been diluted in 10-20 ml of isotonic sodium chloride solution. When the heart rate, dizziness, nausea or slow injection speed switching to drip, then 10-20 ml of the drug (0,24-0,48 g) was diluted in 100-150 ml of isotonic sodium chloride solution; administered at a rate of 30-50 drops per minute. Solution before parenteral administration should be warmed to body temperature.
Aminophylline administered parenterally to 3 times a day, no more than 14 days. Higher doses aminophylline adult veins: single – 0.25 g daily – 0.5 g
The drug is not recommended for children under 14 years because of side effects. However, if necessary children aminophylline administered intravenously at the rate of a single dose of 3.2 mg / kg, preferably dropwise. Higher doses for children intravenously: single – 3 mg / kg daily – the age of 3 months – 0,03-0,06 g, from 4 to 12 months – 0,06-0,09 g, from 2 to 3 years – 0,09-0,12 g, from 4 to 7 years old – 0,12-0,24 mg, from 8 to 18 years – 0.25-0.5 g
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

Grotex Ltd.

There are no reviews yet.

Add your review